Can you provide the average price target for INCYTE CORP stock?
33 analysts have analysed INCY and the average price target is 109.42 USD. This implies a price increase of 12.91% is expected in the next year compared to the current price of 96.91.
NASDAQ:INCY • US45337C1027
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for INCYTE CORP (INCY).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-29 | Oppenheimer | Maintains | Perform -> Perform |
| 2026-04-29 | Stifel | Maintains | Buy -> Buy |
| 2026-04-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-03-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-03-25 | UBS | Maintains | Neutral -> Neutral |
| 2026-03-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-03-16 | Jefferies | Downgrade | Buy -> Hold |
| 2026-03-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-03-05 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2026-02-18 | Barclays | Maintains | Overweight -> Overweight |
| 2026-02-11 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2026-02-11 | Stifel | Maintains | Buy -> Buy |
| 2026-02-11 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-02-06 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-02-05 | HC Wainwright & Co. | Initiate | Buy |
| 2026-02-04 | Barclays | Maintains | Overweight -> Overweight |
| 2026-01-20 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2026-01-13 | TD Cowen | Maintains | Buy -> Buy |
| 2026-01-06 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-12-08 | Mizuho | Upgrade | Neutral -> Outperform |
| 2025-12-08 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-12-08 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-24 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-04 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3.696B 8.87% | 4.241B 14.76% | 5.141B 21.22% | 5.678B 10.44% | 6.302B 10.99% | 6.489B 2.97% | 4.713B -27.37% | 4.869B 3.31% | 5.756B 18.22% | 6.073B 5.51% | 6.286B 3.51% | |
| EBITDA YoY % growth | 734.432M 10.04% | 200.892M -72.65% | 1.436B 614.83% | 1.96B 36.49% | 2.483B 26.68% | 2.697B 8.62% | 1.212B -55.06% | 1.013B -16.42% | 1.069B 5.53% | 1.105B 3.37% | 1.148B 3.89% | |
| EBIT YoY % growth | 651.772M 8.72% | 111.644M -82.87% | 1.343B 1,102.71% | 1.924B 43.29% | 2.401B 24.79% | 2.589B 7.83% | 800.07M -69.10% | 1.179B 47.36% | 1.951B 65.48% | 2.271B 16.40% | 2.506B 10.35% | |
| Operating Margin | 17.64% | 2.63% | 26.12% | 33.89% | 38.10% | 39.90% | 16.98% | 24.21% | 33.90% | 37.40% | 39.87% | |
| EPS YoY % growth | 3.52 26.62% | 1.32 -62.50% | 6.79 414.39% | 7.74 13.99% | 9.14 18.04% | 9.47 3.62% | 3.77 -60.18% | 4.18 10.97% | 7.19 71.91% | 8.13 13.11% | 8.85 8.80% |
All data in USD
| Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.87 19.10% | 2.14 -5.53% | 2.31 28.07% | 2.13 17.50% | 2.32 23.83% | 2.48 16.33% | 3.15 36.73% |
| Revenue Q2Q % growth | 1.389B 14.27% | 1.474B 7.91% | 1.575B 4.52% | 1.391B 9.30% | 1.487B 7.06% | 1.533B 4.00% | 1.622B 2.98% |
| EBITDA Q2Q % growth | 399.5M 12.19% | 525.24M 4.92% | 640.96M 34.33% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 457.27M 47.12% | 514.18M 19.21% | 576.35M 50.14% | 509.04M 51.45% | 578.87M 26.59% | 595.4M 15.80% | 631.12M 9.50% |
All data in USD
33 analysts have analysed INCY and the average price target is 109.42 USD. This implies a price increase of 12.91% is expected in the next year compared to the current price of 96.91.
INCYTE CORP (INCY) will report earnings on 2026-07-27.
The consensus EPS estimate for the next earnings of INCYTE CORP (INCY) is 1.87 USD and the consensus revenue estimate is 1.39B USD.
The number of analysts covering INCYTE CORP (INCY) is 33.